Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US suture makers face product risk regrading

This article was originally published in Clinica

Executive Summary

Manufacturers of eight categories of surgical sutures must conform with new performance, testing and labelling recommendations as of July 3, the FDA has announced. All of the sutures were on the market when the agency first obtained regulatory authority over devices in 1976, and as such were put in a transitional class III (high-risk) category until the FDA could decide on their appropriate classification.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT062396

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel